Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2018
Price : $35 *
At a glance
- Drugs Gefitinib (Primary) ; Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms VICTORY-J
- 01 Feb 2018 Planned End Date changed from 1 Mar 2017 to 20 Feb 2018.
- 01 Feb 2018 Planned primary completion date changed from 1 Jan 2017 to 20 Feb 2018.
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.